Consequently, the European Federation of Neurological Societies recommended additional tests for AD diagnosis, including assessment of brain volumetry using magnetic resonance imaging (MRI) and measurement of tau protein in the CSF (14,15). The gene discussed is MAPT; the disease is Alzheimer disease.